Evi Mercken, PhD
Chief Scientific Officer
Dr. Evi Mercken is CSO at Rejuvenate Biomed and part of the management board. As CSO, she provides directions for the in-silico activities, guidance to C. elegans research, and strategic and executional oversight for mouse experiments. Evi brings over 15 years of international experience in the field of aging. She has extensive expertise in translational research that is focused on the molecular pathways that affect the aging process, and how interventions, including dietary, pharmaceutical, and genetic, can positively impact lifespan and healthspan in mice and humans. Within larger collaborative teams, she has delineated the role of specific factors, e.g., nuclear factor erythroid 2–related factor 2 (Nrf2), on aspects of age-related disease, metabolism, and carcinogenesis. Over the years she received research funding for multiple projects from the Flanders Innovation and Entrepreneurship (VLAIO) and Flanders Research Foundation (FWO). Her broad contributions in the fields of metabolism, degenerative muscle disease, and aging have spearheaded focused translation efforts to improve the quality of life. Evi worked as a postdoc at the National Institute on Aging, US, and holds a PhD in Life Sciences and a master’s degree in Biological Health Sciences from Maastricht University, Netherlands.